Assurex Health, Inc., a Mason, OH-based precision medicine company providing treatment decision support for behavioral health and chronic pain conditions, secured an additional $15 million in equity financing.
Backers included Sequoia Capital, Claremont Creek Ventures, Cincinnati Children’s Hospital Medical Center, Mayo Clinic, and Cross Creek Advisors.
The company will use the funds to continue to increase adoption of GeneSight.
Led by Virginia C. Drosos, President and Chief Executive Officer, Assurex Health provides GeneSight, a test (powered by CPGxTM, a proprietary combinatorial pharmacogenomics technology) that measures multiple genomic variants for each patient and weights them together – rather than one at a time – to provide genetically-driven information for each medication for each patient.
The financing followed the recent enhancement to the GeneSight Psychotropic test, a comprehensive neuropsychiatric pharmacogenomics test which gives healthcare providers an expanded range of options to make medication decisions for patients suffering from depression, anxiety, bipolar disorder, posttraumatic stress disorder (PTSD), schizophrenia, and other behavioral health conditions.
To date, more than 14,000 healthcare providers have used GeneSight to help make treatment decisions for over 230,000 patients across the country.